Nektar Therapeutics NKTR Gain On Sale Of The Huntsville Manufacturing Facility

Other financials

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Market cap$2.19B+1,531%

Enterprise value$2.27B+874%

P/S39.4×+37.8×

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept nktr:GainOnSaleOfTheHuntsvilleManufacturingFacility.

The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Nektar Therapeutics's gain on sale of the huntsville manufacturing facility?: Nektar Therapeutics (NKTR) reported gain on sale of the huntsville manufacturing facility of $0 in Q4 2025.
How has Nektar Therapeutics's gain on sale of the huntsville manufacturing facility changed year-over-year?: Nektar Therapeutics's gain on sale of the huntsville manufacturing facility decreased by 100.0% year-over-year, from $10.1M to $0.